JPWO2020227233A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020227233A5 JPWO2020227233A5 JP2022512708A JP2022512708A JPWO2020227233A5 JP WO2020227233 A5 JPWO2020227233 A5 JP WO2020227233A5 JP 2022512708 A JP2022512708 A JP 2022512708A JP 2022512708 A JP2022512708 A JP 2022512708A JP WO2020227233 A5 JPWO2020227233 A5 JP WO2020227233A5
- Authority
- JP
- Japan
- Prior art keywords
- specific
- neoplasm
- cells
- peptide
- neoepitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 55
- 102000004196 processed proteins & peptides Human genes 0.000 claims 32
- 230000035772 mutation Effects 0.000 claims 24
- 206010028980 Neoplasm Diseases 0.000 claims 23
- 208000035269 cancer or benign tumor Diseases 0.000 claims 21
- 238000000034 method Methods 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 14
- 210000003289 regulatory T cell Anatomy 0.000 claims 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 230000001613 neoplastic effect Effects 0.000 claims 7
- 230000002939 deleterious effect Effects 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000043129 MHC class I family Human genes 0.000 claims 4
- 108091054437 MHC class I family Proteins 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 206010069754 Acquired gene mutation Diseases 0.000 claims 3
- 238000000126 in silico method Methods 0.000 claims 3
- 230000037439 somatic mutation Effects 0.000 claims 3
- 238000012360 testing method Methods 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 102000043131 MHC class II family Human genes 0.000 claims 2
- 108091054438 MHC class II family Proteins 0.000 claims 2
- 108010026552 Proteome Proteins 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000000947 anti-immunosuppressive effect Effects 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000007481 next generation sequencing Methods 0.000 claims 2
- 230000003614 tolerogenic effect Effects 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 239000012648 POLY-ICLC Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 244000005702 human microbiome Species 0.000 claims 1
- 230000005746 immune checkpoint blockade Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108700002563 poly ICLC Proteins 0.000 claims 1
- 229940115270 poly iclc Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962842800P | 2019-05-03 | 2019-05-03 | |
| US62/842,800 | 2019-05-03 | ||
| US201962880965P | 2019-07-31 | 2019-07-31 | |
| US62/880,965 | 2019-07-31 | ||
| US201962932651P | 2019-11-08 | 2019-11-08 | |
| US201962932654P | 2019-11-08 | 2019-11-08 | |
| US62/932,651 | 2019-11-08 | ||
| US62/932,654 | 2019-11-08 | ||
| PCT/US2020/031357 WO2020227233A2 (en) | 2019-05-03 | 2020-05-04 | Neoantigens in cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533861A JP2022533861A (ja) | 2022-07-26 |
| JPWO2020227233A5 true JPWO2020227233A5 (https=) | 2023-05-16 |
| JP2022533861A5 JP2022533861A5 (https=) | 2023-05-16 |
Family
ID=73050870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022512708A Pending JP2022533861A (ja) | 2019-05-03 | 2020-05-04 | がんにおける新抗原 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220125900A1 (https=) |
| EP (2) | EP3963335B1 (https=) |
| JP (1) | JP2022533861A (https=) |
| CA (1) | CA3138867A1 (https=) |
| WO (1) | WO2020227233A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250232833A1 (en) * | 2024-01-13 | 2025-07-17 | Noergaard Anders Kaare | Cyclin D1 Based Cancer Vaccine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008211227B2 (en) * | 2007-01-30 | 2014-04-17 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
| BR112012029066A2 (pt) * | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | composições e processos de identificação de neoantígenos específicos de tumor. |
| CN118750591A (zh) * | 2013-04-07 | 2024-10-11 | 博德研究所 | 用于个性化瘤形成疫苗的组合物和方法 |
| KR102841050B1 (ko) * | 2017-04-19 | 2025-08-01 | 그릿스톤 바이오, 인코포레이티드 | 신생항원 동정, 제조, 및 용도 |
| WO2020176726A1 (en) * | 2019-02-27 | 2020-09-03 | Epivax Oncology, Inc. | Improved compositions and methods for personalized neoplasia vaccines |
-
2020
- 2020-05-04 EP EP20729893.6A patent/EP3963335B1/en active Active
- 2020-05-04 WO PCT/US2020/031357 patent/WO2020227233A2/en not_active Ceased
- 2020-05-04 EP EP22208033.5A patent/EP4198513A1/en not_active Withdrawn
- 2020-05-04 JP JP2022512708A patent/JP2022533861A/ja active Pending
- 2020-05-04 CA CA3138867A patent/CA3138867A1/en active Pending
-
2021
- 2021-11-02 US US17/517,118 patent/US20220125900A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12372533B2 (en) | Identification of immunogenic mutant peptides using genomic, transcriptomic and proteomic information | |
| TWI672503B (zh) | 致免疫性之癌症特異抗原決定位的排名系統 | |
| ES2311710T3 (es) | Procedimiento para la identificacion de peptidos inmunoreactivos. | |
| JP2018530579A (ja) | ウイルス性癌ネオエピトープのための組成物および方法 | |
| RU2004110239A (ru) | Модифицированный фактор ix | |
| RU2020110192A (ru) | Предсказание иммуногенности т-клеточных эпитопов | |
| US20120077696A1 (en) | Soluble hla complexes for use in disease diagnosis | |
| JP6991967B2 (ja) | ウイルスネオエピトープおよびその使用 | |
| EP3881324A1 (en) | Selection of cancer mutations for generation of a personalized cancer vaccine | |
| CN114375397A (zh) | 用于表征肽：mhc结合多肽的方法 | |
| JP2004519230A (ja) | 低減された免疫原性を有する修飾されたインターロイキン−１受容体アンタゴニスト（ｉｌ−１ｒａ） | |
| EP4126013A2 (en) | Tumor antigens for liver cancer immunotherapy | |
| JP2004532618A (ja) | 低減された免疫原性を有する修飾されたレプチン | |
| JPWO2020227233A5 (https=) | ||
| KR20030082962A (ko) | 감소된 면역원성을 갖는 개질된과립구대식세포집락자극인자(ｇｍ-ｃｓｆ) | |
| US20210317533A1 (en) | Unbiased identification of tumor rejection mediating neoepitopes | |
| JP2004529629A (ja) | 低減された免疫原性を有する修飾された繊毛様神経栄養因子（ｃｎｔｆ） | |
| JPWO2021101962A5 (https=) | ||
| Rapberger et al. | Linking the ovarian cancer transcriptome and immunome | |
| CN113272419A (zh) | 制备治疗性t淋巴细胞的方法 | |
| Mahajan et al. | Detecting known neoepitopes, gene fusions, transposable elements, and circular RNAs in cell-free RNA | |
| WO2007043103A1 (ja) | シェーグレン症候群診断法及び診断キット | |
| CA3114265C (en) | Selection of cancer mutations for generation of a personalized cancer vaccine | |
| Zuleger et al. | Discovery of T Cell Epitopes for Cancer Immunotherapy | |
| RU2005100758A (ru) | Способ картирования и устранения эпитопов т-клеток |